CYP2C19基因型与经皮冠状动脉介入术后心肌损伤和远期主要不良心血管事件的研究进展

Research progress of CYP2C19 genotype with myocardial injury and long-term major adverse cardiovascular events after percutaneous coronary intervention

摘要:

经皮冠状动脉介入(PCI)术后患者建议使用双联抗血小板治疗以降低主要不良心血管事件(MACE)的发生风险,但在临床实践过程中,仍有部分患者没有达到预期疗效,出现氯吡格雷抵抗,严重影响患者预后。因此CYP2C19基因型与PCI术后心肌损伤以及远期MACE的关系值得我们进一步探讨,本文将对以上问题作一综述。

Abstract:

Dual antiplatelet therapy is recommended for coronary heart disease patients after percutaneous coronary intervention (PCI) so as to reduce the risk of major adverse cardiovascular events (MACE). However, some patients do not display adequate antiplatelet response and show resistance to clopidogrel, which seriously affecting the prognosis of them. Therefore, it is a practical problem for the relationship between CYP2C19 genetic polymorphisms and myocardial injury after PCI as well as long-term MACE. We reviewed the problem in this article.